DOI QR코드

DOI QR Code

Development of Rapid Antibody-based Therapeutic Platform Correspondence for New Viruses Using Antigen-specific Single Cell Memory B Cell Sorting Technology

항원 특이적 단일 기억 B 세포 분리를 이용한 신종 바이러스 대응 신속 항체 플랫폼 개발

  • Jiyoon Seok (Gene therapy Research Team, Daewoong Pharmaceutical Co, LTD.) ;
  • Suhan Jung (Gene therapy Research Team, Daewoong Pharmaceutical Co, LTD.) ;
  • Ye Gi Han (Gene therapy Research Team, Daewoong Pharmaceutical Co, LTD.) ;
  • Arum Park (Gene therapy Research Team, Daewoong Pharmaceutical Co, LTD.) ;
  • Jung Eun Kim (Chem-Bio Center, Advanced Defense Science & Technology Research Institute, Agency for Defense Development) ;
  • Young Jo Song (Chem-Bio Center, Advanced Defense Science & Technology Research Institute, Agency for Defense Development) ;
  • Chi Ho Yu (Chem-Bio Center, Advanced Defense Science & Technology Research Institute, Agency for Defense Development) ;
  • Hyeongseok Yun (Chem-Bio Center, Advanced Defense Science & Technology Research Institute, Agency for Defense Development) ;
  • Se Hun Gu (Chem-Bio Center, Advanced Defense Science & Technology Research Institute, Agency for Defense Development) ;
  • Seung-Ho Lee (Chem-Bio Center, Advanced Defense Science & Technology Research Institute, Agency for Defense Development) ;
  • Yong Han Lee (Chem-Bio Center, Advanced Defense Science & Technology Research Institute, Agency for Defense Development) ;
  • Gyeunghaeng Hur (Chem-Bio Center, Advanced Defense Science & Technology Research Institute, Agency for Defense Development) ;
  • Woong Choi (Gene therapy Research Team, Daewoong Pharmaceutical Co, LTD.)
  • 석지윤 ((주)대웅제약 유전자신약팀) ;
  • 정수한 ((주)대웅제약 유전자신약팀) ;
  • 한예지 ((주)대웅제약 유전자신약팀) ;
  • 박아름 ((주)대웅제약 유전자신약팀) ;
  • 김정은 (국방과학연구소 국방첨단과학기술연구원 Chem-Bio센터) ;
  • 송영조 (국방과학연구소 국방첨단과학기술연구원 Chem-Bio센터) ;
  • 유치호 (국방과학연구소 국방첨단과학기술연구원 Chem-Bio센터) ;
  • 윤형석 (국방과학연구소 국방첨단과학기술연구원 Chem-Bio센터) ;
  • 구세훈 (국방과학연구소 국방첨단과학기술연구원 Chem-Bio센터) ;
  • 이승호 (국방과학연구소 국방첨단과학기술연구원 Chem-Bio센터) ;
  • 이용한 (국방과학연구소 국방첨단과학기술연구원 Chem-Bio센터) ;
  • 허경행 (국방과학연구소 국방첨단과학기술연구원 Chem-Bio센터) ;
  • 최웅 ((주)대웅제약 유전자신약팀)
  • Received : 2023.10.24
  • Accepted : 2024.01.02
  • Published : 2024.02.05

Abstract

The COVID-19 pandemic is not over despite the emergency use authorization as can see recent COVID-19 daily confirmed cases. The viruses are not only difficult to diagnose and treat due to random mutations, but also pose threat human being because they have the potential to be exploited as biochemical weapons by genetic manipulation. Therefore, it is inevitable to the rapid antibody-based therapeutic platform to quickly respond to future pandemics by new/re-emerging viruses. Although numerous researches have been conducted for the fast development of antibody-based therapeutics, it is sometimes hard to respond rapidly to new viruses because of complicated expression or purification processes for antibody production. In this study, a novel rapid antibody-based therapeutic platform using single B cell sorting method and mRNA-antibody. High immunogenicity was caused to produce antibodies in vivo through mRNA-antigen inoculation. Subsequently, antigen-specific antibody candidates were selected and obtained using isolation of B cells containing antibody at the single cell level. Using the antibody-based therapeutic platform system in this study, it was confirmed that novel antigen-specific antibodies could be obtained in about 40 days, and suggested that the possibility of rapid response to new variant viruses.

Keywords

Acknowledgement

본 연구는 국방과학연구소의 지원을 받아 수행하였다(UE211112ZD, 311KK5-912888601).

References

  1. Cupertino MC, Resende MB, Mayer NAJ, Carvalho LM, Siqueira-Batista R, "Emerging and re-emerging human infectious diseases: A systematic review of the role of wild animals with a focus on public health impact," Asian Pac J Trop Med., Vol. 13, pp. 99-106, 2020. https://doi.org/10.4103/1995-7645.277535
  2. Simpson S, Kaufmann MC, Glozman V, Chakrabarti A, "Disease X: accelerating the development of medical countermeasures for the next pandemic," Lancet Infect Dis., Vol. 20, pp. e108-e115, 2020. https://doi.org/10.1016/S1473-3099(20)30123-7
  3. National Academies of Sciences E, Medicine, Division on E, Life S, Board on Life S, Board on Chemical S, et al., In: Biodefense in the Age of Synthetic Biology, pp. 23-92, 2018. 
  4. Noyce RS, Lederman S, Evans DH, "Construction of an infectious horsepox virus vaccine from chemically synthesized DNA fragments," PLOS ONE, Vol. 13, p. e0188453, 2018. 
  5. Wu F, Zhao S, Yu B, Chen Y-M, Wang W, Song Z-G, et al., "A new coronavirus associated with human respiratory disease in China," Nature, Vol. 579, pp. 265-269, 2020. https://doi.org/10.1038/s41586-020-2008-3
  6. Singh JA, Upshur REG, "The granting of emergency use designation to COVID-19 candidate vaccines: implications for COVID-19 vaccine trials," Lancet Infect Dis., Vol. 21, pp. e103-e109, 2021.  https://doi.org/10.1016/S1473-3099(20)30923-3
  7. Lamb YN, "BNT162b2 mRNA COVID-19 Vaccine: First Approval," Drugs, Vol. 81, pp. 495-501, 2021.  https://doi.org/10.1007/s40265-021-01480-7
  8. Wang H, Li X, Li T, Zhang S, Wang L, Wu X, et al., "The genetic sequence, origin, and diagnosis of SARS-CoV-2," Eur J Clin Microbiol Infect Dis., Vol. 39, pp. 1629-1635, 2020. https://doi.org/10.1007/s10096-020-03899-4
  9. Kalia K, Saberwal G, Sharma G, "The lag in SARS-CoV-2 genome submissions to GISAID," Nat Biotechnol., Vol. 39, pp. 1058-1060, 2021.  https://doi.org/10.1038/s41587-021-01040-0
  10. Ling Y, Zhong J, Luo J, "Safety and effectiveness of SARS-CoV-2 vaccines: A systematic review and meta-analysis," J Med Virol., Vol. 93, pp. 6486-6495, 2021.  https://doi.org/10.1002/jmv.27203
  11. Li Y, Tenchov R, Smoot J, Liu C, Watkins S, Zhou Q, "A Comprehensive Review of the Global Efforts on COVID-19 Vaccine Development," ACS Cent Sci., Vol. 7, pp. 512-533, 2021.  https://doi.org/10.1021/acscentsci.1c00120
  12. Birch JR, Racher AJ, "Antibody production," Adv Drug Deliv Rev., Vol. 58, pp. 671-685, 2006.  https://doi.org/10.1016/j.addr.2005.12.006
  13. Goodnow CC, Vinuesa CG, Randall KL, Mackay F, Brink R, "Control systems and decision making for antibody production," Nat Immunol., Vol. 11, pp. 681-688, 2010.  https://doi.org/10.1038/ni.1900
  14. Deng Y-Q, Zhang N-N, Zhang Y-F, Zhong X, Xu S, Qiu H-Y, et al., "Lipid nanoparticle-encapsulated mRNA antibody provides long-term protection against SARS-CoV-2 in mice and hamsters," Cell Res., Vol. 32, pp. 375-382, 2022.  https://doi.org/10.1038/s41422-022-00630-0
  15. Rybakova Y, Kowalski PS, Huang Y, Gonzalez JT, Heartlein MW, DeRosa F, et al., "mRNA Delivery for Therapeutic Anti-HER2 Antibody Expression In Vivo," Mol Ther., Vol. 27, pp. 1415-1423, 2019.  https://doi.org/10.1016/j.ymthe.2019.05.012
  16. Stadler CR, Bahr-Mahmud H, Celik L, Hebich B, Roth AS, Roth RP, et al., "Elimination of large tumors in mice by mRNA-encoded bispecific antibodies," Nat Med., Vol. 23, pp. 815-817, 2017.  https://doi.org/10.1038/nm.4356
  17. Deal CE, Carfi A, Plante OJ, "Advancements in mRNA Encoded Antibodies for Passive Immunotherapy," Vaccines, Vol. 9, p. 108, 2021. 
  18. Tiller T, Busse CE, Wardemann H, "Cloning and expression of murine Ig genes from single B cells," J Immunol Methods, Vol. 350, pp. 183-193, 2009.  https://doi.org/10.1016/j.jim.2009.08.009
  19. Walker SE, Lorsch J. Chapter Nineteen - RNA Purification - Precipitation Methods. In: Lorsch J, editor. Meth. Enzymol. Academic Press; 2013, pp. 337-34. 
  20. Hassett KJ, Benenato KE, Jacquinet E, Lee A, Woods A, Yuzhakov O, et al., "Optimization of Lipid Nanoparticles for Intramuscular Administration of mRNA Vaccines," Mol Ther Nucleic Acids, Vol. 15, pp. 1-11, 2019.  https://doi.org/10.1016/j.omtn.2019.01.013
  21. Kizzmekia SC, Darin E, Sarah RL, Olubukola MA, Seyhan B-B, Rebecca AG, et al., "SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness," bioRxiv, Vol., pp. 2020. 2006.2011.145920, 2020.